Contraindicated in:
Use Cautiously in:
CV: MI, CARDIOVASCULAR DEATH, DEEP VEIN THROMBOSIS (DVT), hypertension.
Derm: acne, contact dermatitis, impetigo.
EENT: nasopharyngitis, retinal detachment.
GI: nausea, abdominal pain, oropharyngeal pain, vomiting.
Hemat: lymphopenia, thrombocytopenia.
Metab: hyperlipidemia.
MS: ↑ creatine kinase.
Neuro: dizziness, fatigue, headache.
Resp: PULMONARY EMBOLISM (PE).
Misc: INFECTION (INCLUDING TUBERCULOSIS, BACTERIAL, INVASIVE FUNGAL, VIRAL, OR OPPORTUNISTIC INFECTIONS), MALIGNANCY(INCLUDING NON-MELANOMA SKIN CANCER).
Drug-Drug:
Renal Impairment
Absorption: Well absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Metabolism/Excretion: Primarily metabolized by the liver via the CYP2C19, CYP2C9, CYP3A4, and CYP2B6 isoenzymes into two active metabolites (M1 and M2). 2% of Whites, 4% of Blacks, and 14% of Asians have CYP2C19 genotype that results in reduced metabolism of abrocitinib.Primarily excreted in urine (<1% as unchanged drug).
Half-life: 35 hr.